| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | JUP |
| Uniprot No | P14923 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-745aa |
| 氨基酸序列 | MEVMNLMEQP IKVTEWQQTY TYDSGIHSGA NTCVPSVSSK GIMEEDEACG RQYTLKKTTT YTQGVPPSQG DLEYQMSTTA RAKRVREAMC PGVSGEDSSL LLATQVEGQA TNLQRLAEPS QLLKSAIVHL INYQDDAELA TRALPELTKL LNDEDPVVVT KAAMIVNQLS KKEASRRALM GSPQLVAAVV RTMQNTSDLD TARCTTSILH NLSHHREGLL AIFKSGGIPA LVRMLSSPVE SVLFYAITTL HNLLLYQEGA KMAVRLADGL QKMVPLLNKN NPKFLAITTD CLQLLAYGNQ ESKLIILANG GPQALVQIMR NYSYEKLLWT TSRVLKVLSV CPSNKPAIVE AGGMQALGKH LTSNSPRLVQ NCLWTLRNLS DVATKQEGLE SVLKILVNQL SVDDVNVLTC ATGTLSNLTC NNSKNKTLVT QNSGVEALIH AILRAGDKDD ITEPAVCALR HLTSRHPEAE MAQNSVRLNY GIPAIVKLLN QPNQWPLVKA TIGLIRNLAL CPANHAPLQE AAVIPRLVQL LVKAHQDAQR HVAAGTQQPY TDGVRMEEIV EGCTGALHIL ARDPMNRMEI FRLNTIPLFV QLLYSSVENI QRVAAGVLCE LAQDKEAADA IDAEGASAPL MELLHSRNEG TATYAAAVLF RISEDKNPDY RKRVSVELTN SLFKHDPAAW EAAQSMIPIN EPYGDDMDAT YRPMYSSDVP LDPLEMHMDM DGDYPIDTYS DGLRPPYPTA DHMLA |
| 预测分子量 | 81,7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于JUP(Junction Plakoglobin)重组蛋白的模拟参考文献示例，供参考。建议通过PubMed、Google Scholar等平台查询真实文献：
---
1. **标题**：*Recombinant Plakoglobin Expression in E. coli and Its Role in Cell-Cell Adhesion*
**作者**：Smith A, et al.
**摘要**：研究通过大肠杆菌系统表达重组JUP蛋白，优化纯化条件，并验证其在体外促进上皮细胞粘附的功能，表明重组JUP可修复缺乏细胞连接的细胞模型。
2. **标题**：*Structural Insights into Plakoglobin-Catenin Interactions via Recombinant Protein Analysis*
**作者**：Lee B, et al.
**摘要**：利用重组JUP蛋白进行X射线晶体学研究，解析其与β-catenin的结合结构，揭示二者相互作用的关键位点，为相关癌症机制提供依据。
3. **标题**：*Plakoglobin Recombinant Therapy in Epidermolysis Bullosa*
**作者**：Zhang Y, et al.
**摘要**：在小鼠模型中评估重组JUP蛋白的基因治疗效果，证明其能改善皮肤细胞连接缺陷，为治疗大疱性表皮松解症提供潜在策略。
4. **标题**：*JUP Regulates Wnt Signaling via Recombinant Protein Reconstitution*
**作者**：Green KJ, et al.
**摘要**：通过体外重建实验，发现重组JUP蛋白可竞争性抑制Wnt通路中β-catenin的核转位，提示其在信号调控中的双重作用。
---
注意：以上为模拟文献，实际研究需查阅权威数据库。建议结合关键词“JUP/Plakoglobin recombinant protein”或“recombinant Junction Plakoglobin”进行检索。
**Background of JUP Recombinant Protein**
JUP (Junction Plakoglobin), also known as γ-catenin, is a key component of cell-cell adhesion structures, particularly desmosomes and adherens junctions. It belongs to the armadillo protein family and shares structural homology with β-catenin. JUP plays dual roles: maintaining tissue integrity by linking cadherins to the cytoskeleton and participating in intracellular signaling pathways, notably the Wnt/β-catenin pathway. Its dysfunction is linked to various diseases, including arrhythmogenic cardiomyopathy (AC), skin disorders, and cancer.
The development of recombinant JUP protein stems from the need to study its molecular mechanisms and therapeutic potential. Recombinant JUP is produced using expression systems like *E. coli* or mammalian cells, enabling high-purity, scalable yields for research. This engineered protein retains functional domains critical for interactions with binding partners, such as cadherins, α-catenin, and desmoplakin, making it invaluable for *in vitro* assays, structural studies, and drug screening.
In disease research, recombinant JUP aids in elucidating how mutations disrupt cell adhesion and signaling. For instance, in AC, JUP mutations impair desmosomal function, leading to cardiomyocyte detachment and fibrosis. Recombinant protein models help identify rescue strategies or small molecules to stabilize intercellular junctions. In oncology, JUP's role as a tumor suppressor or promoter (context-dependent) is explored using recombinant forms to decipher its interplay with oncogenic pathways.
Therapeutic applications are emerging, with recombinant JUP tested in gene/protein replacement therapies or as a biologic to restore tissue homeostasis. Challenges remain in delivery efficiency and stability *in vivo*, but advancements in protein engineering and nanotechnology hold promise. Overall, JUP recombinant protein serves as a vital tool bridging basic research and translational innovation in cardiovascular, dermatological, and cancer therapeutics.
×
